Filed 26 May 95
Serial No. 08/451,641 (DIV of 08/245,923)

The invention concerns a series of pteridine deoxyribonucleotide analogs which are highly fluorescent and resemble purine nucleotides in chemical structure and properties. The phosphoramidite form of these fluorophores can be site-specifically incorporated into oligonucleotides using conventional DNA synthesis techniques. The fluorescence intensity of the pteridine nucleotide analogs is highly dependent on their physicochemical environment, thus making them ideal for the study of DNA-protein interactions. A real-time assay for HIV integrase has been developed using one of the pteridine nucleotide analogs that resembles guanosine. Other uses foreseen are as fluorescent labels for DNA probes and PCR primers and for investigating protein-DNA interactions. The claims include the phosphoramidite derivatives of the pteridine nucleotide analogs useful as starting materials for oligonucleotide synthesis and oligonucleotides incorporating the pteridine nucleotide analogs. (portfolio: Gene-Based Therapies—Research Tools and Reagents; Gene-Based Therapies—Diagnostics)

Dated: February 1, 1996.

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 96–3073 Filed 2–9–96; 8:45 am]

BILLING CODE 4140–01–M

National Heart, Lung, and Blood Institute; Notice of a Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Heart, Lung, and Blood Special Emphasis Panel (SEP) meeting:

Name of SEP: Review of Tuberculosis Academic Award Applications.

Date: March 5, 1996.

Time: 9:00 a.m.

Place: Holiday Inn Chevy Chase, Chevy Chase, Maryland.

Contact Person: Louise P. Corman, Ph.D., Two Rockledge Center, Room 7180, 6701 Rockledge Drive, Bethesda, MD 20892–7924, (301) 435–0270.

Purpose/Agenda: To review and evaluate grant applications.

The meeting will be closed in accordance with the provisions set forth in sec. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; and 93.839, Blood Diseases and Resources Research, National Institutes of Health)

Dated: February 6, 1996.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 96–3071 Filed 2–9–96; 8:45 am]

BILLING CODE 4140–01–M

National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings:

Name of Committee: National Diabetes and Digestive and Kidney Diseases Special Grants Review Committee, Subcommittee B.

Date: March 7–8, 1996.

Time: 5 p.m.–adjournment on March 8.

Place: Embassy Suites Hotel, 4300 Military Road, NW., Washington, DC 20015.

Contact Person: Ned Feder, Ph.D., Natcher Building, Room 6AS–25S, National Institutes of Health, Bethesda, Maryland 20892–6600, Phone: 301–594–8890.

Purpose/Agenda: To review and evaluate research grant applications.

Name of Committee: National Diabetes and Digestive and Kidney Diseases Special Grants Review Committee, Subcommittee C.

Date: February 29–March 1, 1996.

Time: 8:30 a.m.–adjournment.

Place: Stouffer Mayflower Hotel, 1127 Connecticut Ave., NW., Washington, DC 20036.

Contact Person: Daniel Matsumoto, Ph.D., Natcher Building, Room 6AS–37B, National Institutes of Health, Bethesda, Maryland 20892–6600, Phone: 301–594–8894.

Purpose/Agenda: To review and evaluate research grant applications.

Name of Committee: National Diabetes and Digestive and Kidney Diseases Special Grants Review Committee, Subcommittee D.

Date: March 1, 1996.

Time: 8 a.m.–adjournment.

Place: Holiday Inn Chevy Chase, 5520 Wisconsin Avenue, Chevy Chase, Maryland 20815.

Contact Person: Ann A. Hagan, Ph.D., Natcher Building, Room 6AS–43G, National Institutes of Health, Bethesda, Maryland 20892–6600, Phone: 301–594–8891.

Purpose/Agenda: To review and evaluate research grant applications.

The meetings will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program No. 93.847–849, Diabetes, Endocrine and Metabolic Diseases; Digestive Diseases and Nutrition; and Kidney Diseases, Urology and Hematology Research, National Institutes of Health)

Dated: February 6, 1996.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 96–3072 Filed 2–9–96; 8:45 am]

BILLING CODE 4140–01–M

Prospective Grant of Exclusive License: Cartilage-Derived Morphogenetic Proteins

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

SUMMARY: This is notice in accordance with 15 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive license in the United States to practice the invention embodied in U.S. Public Health Service Employee Invention Report Number E–138–94/0 (PCT/US94/12814), entitled ''Cartilage-Derived Morphogenetic Proteins'' to Creative BioMolecules, Inc., having a place of business in Hopkinton, Massachusetts. The patent rights in this application have been assigned to the United States of America.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 60 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

The present invention relates generally to the field of cartilage and bone development. More specifically, this invention relates to cartilage-derived morphogenetic proteins (CDMPs) that stimulate development and repair of cartilage *in vivo.* These proteins which exhibit chondrogenic properties are disclosed to be members of the TGF–B superfamily. Also disclosed are polynucleotides encoding two members of the CDMP family of proteins. Recombinant CDMP–1 protein was shown to have chondrogentic activity *in vivo.* The primary uses of this invention would be in orthopaedic reconstruction.